NED Medical
NED Medical: Revolutionizing oncology with curative-intent embolization equipment for unresectable tumors.
Founded
2022NED Medical: Revolutionizing oncology with curative-intent embolization equipment for unresectable tumors.
NED Medical, founded with a mission to revolutionize oncology treatment, focuses on manufacturing advanced embolization equipment aimed at transforming oncology embolization therapy from palliative to curative-intent. Their primary product line targets the treatment of unresectable tumors, particularly liver cancer, with the goal of significantly improving patient outcomes. The company is dedicated to addressing the critical need for better survival rates in liver cancer, which currently has a dismal 5-year survival rate of 15.6%.
Notable figures affiliated with NED Medical include leading oncologists and medical device experts who contribute to the development and refinement of their innovative technologies. The company has garnered attention from prominent investors in the healthcare sector, reflecting confidence in its potential impact. Key achievements include the development and successful deployment of their flagship product, CombiSphere, which has shown promise in clinical trials. Overall, NED Medical is making significant strides in the field of oncology, offering hope for improved treatment options for patients worldwide.
Companies similar to NED Medical include Nemedio, NED Biosystems, Embolx and Nectero Medical.
NED Medical was founded in 2022.
NED Medical's headquarters is located in Norwell, MA, US.
NED Medical's most recent funding round was for $500k (USD) in August 2023.
As of Aug 28, 2023, NED Medical has disclosed funding of $500k (USD). Undisclosed round amounts are excluded.
NED Medical has 1 employee as of Feb 5, 2024.
Nectero Medical
necteromed.com
